Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foreign Firms Not Fatigued In India, Game For 'New Things'

Executive Summary

Senior management executives of Roche, Bayer, AstraZeneca, Pfizer and Novo Nordisk in India signal momentum in product launch and clinical trial activity, belying apprehension of wider cutbacks by foreign firms in the country, though one executive stressed that “tried and tested models” may not work in the largely self-pay market.

You may also be interested in...



Takeda Expands Hemophilia Play In India But Hemlibra Has Made Inroads

Takeda dips into the ex-Shire portfolio to debut Adynovate in India, where a large number of hemophilia patients remain undiagnosed. The extended half-life recombinant Factor VIII treatment, though, will need to take on competitors like Roche’s blockbuster, Hemlibra, which has seen rapid adoption in reimbursement ecosystems where it is included in the formulary

Pfizer Latest Foreign Firm To Axe India Field Force Jobs: Here’s The Big Picture Take

Pfizer effects hundreds of field force job cuts in India as it rewires its commercialization approach and creates new roles leveraging its ‘digital core’, but industry experts suggest there is a complex mix of other factors at play as well.

Can Roche’s Phesgo Mirror UK Adoption Trend in India?

Roche debuts ‘responsibly priced’ Phesgo in India. Will the dramatic reduction in treatment time for women with HER2 positive breast cancer and other benefits, including insurance coverage, trigger sharp shifts towards the subcutaneous fixed-dose combination of Perjeta and Herceptin?

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC146124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel